Press Clipping: New Revolutionary Tools - GHP Magazine, November 2017

Information Materials / Media Corner


Share on Social Networks

Share Link

Use permanent link to share in social media

Share with a friend

Please login to send this document by email!

Embed in your website

Select page to start with

2. GHP / November 2017 23 New Revolutionary Tools for Pharma and Medical Researchers Ready to Go Further g Name: Alexander Serre Position: Sales & Marketing Director Email: Websites: & Address: Sägereistrasse 25, 8152 Glattbrugg, Switzerland Telephone: +41 43 544 87 10 of which would not have been possible had it not been for FluidFM. The product allows companies conducting research to break boundaries and go beyond current limits in their investigations. Having built a solid foundation over the past decade, the challenge for Cytosurge in the coming years is to further expand the availability of FluidFM around the world, carefully selecting the routes to market, and building solid distribution and technical support partnerships around the globe. The company fully supports the technical demands that such an advanced and unique technology generates. A brand new BSL-2 Bio Lab has recently been opened at the headquarters near Zurich airport, which allows future customers and partners to test the suitability of the technology for their needs before buying. It can equally perform sub-contracting for researchers who are waiting for their grants to come through. Looking ahead, the FluidFM journey has, so far, been a step by step growth plan centred around a unique technology, with proven advantages for researchers, conducted by a hand-picked team of experts, each specialist in his/ her domain, and driven by a modern management style that encourages team-work and empowers the individual. From these solid foundations, a structured international development plan over the next five years is being implemented.

1. 22 GHP / November 2017 , 1708BU02 New Revolutionary Tools for Pharma and Medical Researchers Ready to Go Further Cytosurge was founded in 2009, and has invested considerable time and money to turn a laboratory idea into a commercially viable technology. We profiled the firm in order to find out what clients can expect when working with the company. Cytosurge manufactures and distributes patented hollow FluidFM ® nanopipettes and nanosyringes with apertures ranging from a few microns to 300 nanometres, as well as the associated equipment for its implementation. To put that into perspective, 300 nm is approximately 200 times smaller than the diameter of a human hair! The company is a Swiss-based SME, consisting of around 20 employees, although this number is fast increasing at the rate of one person per month since the beginning of 2017. With a solid entrepreneurial financial backing, along with its well- known Swiss high-precision, the company is set to take on the rapidly expanding order book, as the fame and reputation of the patented FluidFM technology spreads across research laboratories all over the globe. The company is already successful in several key markets with close to 50 systems already in use throughout Europe, Asia and the United States, and with high hopes of obtaining the first installations on the African and Australian continents before the end of the year. For many years, Pharma and Medical researchers have been studying phenomena at the limit of current technology. For example, the targeted introduction of drugs into pre- selected, individual cells, or the extraction cell content for downstream analysis. These pioneer research topics brought with them a number of additional questions such as “How can I introduce a precise volume of a drug in a single cell in a fast and reliable way?”, “How much of a drug do I need in a cell for it to be active?” or “How can I identify what changes occur in a single cell after introduction of a drug?” These questions can now be answered using FluidFM technology. FluidFM nanosyringes are filled with a fluid, to which positive or negative pressure can be applied through the company’s specially designed Pressure Controller. In this way, measurable sub- picolitre volumes can be injected into or extracted from the nucleoplasm, and cytoplasm of single living cells allowing cellular heterogeneity to be assessed without killing the cells. Single cell isolation and manipulation is also possible using FluidFM nanopipettes. The complete FluidFM BOT system is entirely designed in-house by the company’s engineers, and managed by a specific user-friendly software, allowing researchers to perform repeated single cell manipulations and analysis of up to 100 cells per hour. The exceptional combination of accuracy, precision, repeatability and speed is made possible by the BOT. A further advantage of FluidFM is that it can be used for a variety of other applications, such as single cell and bacteria adhesion, nanolithography, spotting, colloidal spectroscopy and other Bioscience and Biophysical applications. The patented FluidFM probes (nanopipettes and nanosyringes) can also be used on Cytosurge’s cost-effective range of ADD-ON kits which fit many major atomic force microscopes. Alongside having been awarded several prizes for innovation, the firm is part of a number of prestigious partnerships with some of the top universities in the world, in particular ETH Zurich where the technology was born. FluidFM technology has entered the industrial arena through a first collaboration with a world-leading Pharmaceutical company. Additionally, the FluidFM probes can be filled with electroplating solutions. When a minute pressure and an electrical voltage are applied, it is possible to build solid metal 3D micro- structures of virtually any shape. Once again, Cytosurge is entering uncharted territories. The award-winning FluidFM 3Dprinter prints the smallest solid metal structures of any 3D printer to date – and it does it at room temperature. FluidFM has contributed to many research projects, some


  • 2710 Total Views
  • 2000 Website Views
  • 710 Embedded Views


  • 0 Social Shares
  • 0 Dislikes

Share count

  • 0 Facebook
  • 0 Twitter
  • 0 LinkedIn
  • 0 Google+

Embeds 1

  • 16